Scarica l'app Stockscreener
15.50
3.97%
-0.64
Dopo l'orario di chiusura:
15.50
Precedente Chiudi:
$16.14
Aprire:
$15.8
Volume 24 ore:
182.07K
Relative Volume:
0.82
Capitalizzazione di mercato:
$2.01B
Reddito:
$65.48M
Utile/perdita netta:
$-94.46M
Rapporto P/E:
-21.02
EPS:
-0.7375
Flusso di cassa netto:
$-71.18M
1 W Prestazione:
-9.57%
1M Prestazione:
-7.07%
6M Prestazione:
-1.52%
1 anno Prestazione:
-0.39%
Intervallo 1D:
$15.45
$15.80
Intervallo di 1 settimana:
$15.45
$17.34
Portata 52W:
$13.05
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Nome
Mesoblast Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare MESO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.50 | 2.10B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-12-23 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-24 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-23 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Downgrade | Maxim Group | Buy → Hold |
| 2023-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Iniziato | William Blair | Outperform |
| 2022-12-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-06 | Iniziato | Piper Sandler | Overweight |
| 2021-04-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-12-22 | Downgrade | Maxim Group | Buy → Hold |
| 2020-12-04 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2020-05-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-31 | Ripresa | H.C. Wainwright | Buy |
| 2018-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-08-31 | Iniziato | Oppenheimer | Outperform |
| 2017-06-08 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Mesoblast Ltd Adr Borsa (MESO) Ultime notizie
Mesoblast LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Arena Pharmaceuticals Inc (ARNA) Peer Comparison – Compare with Others - Value Research
Earnings call transcript: Mesoblast posts $115 million in FY2026 revenue, stock slips - Investing.com
Mesoblast FY2026 slides: $115M revenue marks commercial transition - Investing.com
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment - Sahm
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times Australia
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - tradingview.com
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SK Hynix Nasdaq debut: $26.5 billion ADR listing sets record - Yahoo Finance
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast (ASX:MSB): The Stem Cell Therapy Company on the Cusp of Commercial Reality - Kalkine
ASX Biotech Stocks to Watch in July 2026 - Kalkine
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs - Barchart.com
Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade - Kalkine
LWB1 Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LSX:A4004R) - TradingView
A4004R Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LS:A4004R) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (NASDAQ:MESO) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (GETTEX:LWB1) - TradingView
Mesoblast Ltd consensus and trial focus, shares watched on Nasdaq - Ad-hoc-news.de
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
MESO - Finviz
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - Barchart.com
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Mesoblast Ltd Adr Azioni (MESO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):